BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33705358)

  • 1. Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva.
    Williams E; Bagarova J; Kerr G; Xia DD; Place ES; Dey D; Shen Y; Bocobo GA; Mohedas AH; Huang X; Sanderson PE; Lee A; Zheng W; Economides AN; Smith JC; Yu PB; Bullock AN
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33705358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
    Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
    J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
    Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
    Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
    Hino K; Zhao C; Horigome K; Nishio M; Okanishi Y; Nagata S; Komura S; Yamada Y; Toguchida J; Ohta A; Ikeya M
    Stem Cell Reports; 2018 Nov; 11(5):1106-1119. PubMed ID: 30392977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
    Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC
    Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.
    Yamamoto M; Stoessel SJ; Yamamoto S; Goldhamer DJ
    J Bone Miner Res; 2022 Nov; 37(11):2077-2093. PubMed ID: 35637634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1
    Wentworth KL; Lalonde RL; Groppe JC; Brewer N; Moody T; Hansberry S; Taylor KE; Shore EM; Kaplan FS; Pignolo RJ; Yelick PC; Hsiao EC
    J Bone Miner Res; 2022 Nov; 37(11):2058-2076. PubMed ID: 36153796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hints on transcriptional control of essential players in heterotopic ossification of Fibrodysplasia Ossificans Progressiva.
    Ravazzolo R; Cappato S; Bocciardi R
    Bone; 2018 Apr; 109():187-191. PubMed ID: 29100956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent progress in drug development for fibrodysplasia ossificans progressiva.
    Meng X; Wang H; Hao J
    Mol Cell Biochem; 2022 Oct; 477(10):2327-2334. PubMed ID: 35536530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice.
    Lounev V; Groppe JC; Brewer N; Wentworth KL; Smith V; Xu M; Schomburg L; Bhargava P; Al Mukaddam M; Hsiao EC; Shore EM; Pignolo RJ; Kaplan FS
    J Bone Miner Res; 2024 May; 39(4):382-398. PubMed ID: 38477818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro-adipogenic progenitors in fibrodysplasia ossificans progressiva mice.
    Lees-Shepard JB; Stoessel SJ; Chandler JT; Bouchard K; Bento P; Apuzzo LN; Devarakonda PM; Hunter JW; Goldhamer DJ
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35503416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP).
    Wang H; Shore EM; Pignolo RJ; Kaplan FS
    Bone; 2018 Apr; 109():218-224. PubMed ID: 29170109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
    van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
    J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).
    Towler OW; Shore EM
    Dev Dyn; 2022 Jan; 251(1):164-177. PubMed ID: 34133058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
    Chakkalakal SA; Shore EM
    Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.
    Davis AJ; Brooijmans N; Brubaker JD; Stevison F; LaBranche TP; Albayya F; Fleming P; Hodous BL; Kim JL; Kim S; Lobbardi R; Palmer M; Sheets MP; Vassiliadis J; Wang R; Williams BD; Wilson D; Xu L; Zhu XJ; Bouchard K; Hunter JW; Graul C; Greenblatt E; Hussein A; Lyon M; Russo J; Stewart R; Dorsch M; Guzi TJ; Kadambi V; Lengauer C; Garner AP
    Sci Transl Med; 2024 May; 16(749):eabp8334. PubMed ID: 38809966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic stem-cell contribution to ectopic skeletogenesis.
    Kaplan FS; Glaser DL; Shore EM; Pignolo RJ; Xu M; Zhang Y; Senitzer D; Forman SJ; Emerson SG
    J Bone Joint Surg Am; 2007 Feb; 89(2):347-57. PubMed ID: 17272450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia ossificans progressiva.
    Cappato S; Tonachini L; Giacopelli F; Tirone M; Galietta LJ; Sormani M; Giovenzana A; Spinelli AE; Canciani B; Brunelli S; Ravazzolo R; Bocciardi R
    Dis Model Mech; 2016 Jun; 9(6):685-96. PubMed ID: 27125279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatial patterns of heterotopic ossification in fibrodysplasia ossificans progressiva correlate with anatomic temperature gradients.
    Wang H; De Cunto CL; Pignolo RJ; Kaplan FS
    Bone; 2021 Aug; 149():115978. PubMed ID: 33915334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
    Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
    J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.